The US FDA has cleared Spero’s IND application to develop SPR206, next-generation polymyxin therapy, in P-II trial SPR206 to treat hospital-acquired & ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR gram-negative bacterial infections
The P-II trial will assess the safety, tolerability, efficacy & PK of SPR206 combined with selected antibiotics for treating HABP or VABP patients (n=60)
Additionally, Pfizer holds the global (excl. US & Asia) rights for developing, manufacturing & commercializing SPR206. Spero will receive ~$80M as development & sales milestones plus high single-digit to low double-digit net sales-based royalties in these regions
Ref: Spero Therapeutics | Image: Spero Therapeutics
Related Post:- GSK Entered into an Exclusive License Agreement with Spero Therapeutics for Tebipenem HBr to Treat Urinary Tract Infections
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
